Welcome to our dedicated page for X4 Pharmaceuticals SEC filings (Ticker: XFOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. X4 is a biopharmaceutical issuer focused on rare hematology diseases and rare diseases of the immune system, and its filings offer detailed insight into how it reports on the development and commercialization of mavorixafor (marketed in the U.S. as XOLREMDI® in its first indication), its chronic neutropenia clinical programs, and its capital structure.
Through Forms 10‑K and 10‑Q, X4 outlines its business description, risk factors, financial condition, and progress in advancing CXCR4‑targeted therapies. Current reports on Form 8‑K, several of which are summarized in the materials provided, disclose material events such as private placements of common stock and pre‑funded warrants, an underwritten public offering, an equity purchase agreement with Lincoln Park Capital Fund, LLC, strategic restructuring actions including a workforce reduction, and changes in executive and board leadership. These filings also reference press releases that contain financial results, trial updates, and other corporate developments.
Investors interested in X4’s clinical and regulatory trajectory can use the filings to follow disclosures related to the global, pivotal Phase 3 4WARD trial in chronic neutropenia, Phase 2 data presentations, and the company’s description of chronic neutropenia and the CXCR4/CXCL12 axis. Proxy and compensation‑related documents, when filed, provide additional detail on governance and executive arrangements, while Forms 4 and related ownership filings (when available) show reportable insider transactions in XFOR stock.
Stock Titan enhances these documents with AI‑powered summaries that highlight key points from lengthy filings, including major financing terms, restructuring details, and clinical program references. Real‑time updates from EDGAR ensure that new X4 Pharmaceuticals filings, from quarterly reports to 8‑Ks describing material agreements, appear promptly, allowing users to quickly understand how regulatory disclosures relate to the company’s rare hematology and CXCR4‑focused strategy.
Trails Edge reports a 9.9% passive stake in X4 Pharmaceuticals. The filing shows Trails Edge Biotechnology Master Fund, LP directly holds 1,571,478 common shares and 745,675 shares underlying prefunded warrants, totaling 2,317,153 shares, which represent 9.9% of the outstanding common stock as of the Event Date. Trails Edge Capital Partners, LP (investment manager) and Ortav Yehudai (CIO) each may be deemed to beneficially own the same amount because of managerial and voting discretion. The filing discloses an issuance limitation that excludes 1,910,069 warrant shares from beneficial ownership calculations to avoid exceeding 9.99%.
Coastlands Capital and affiliated persons report acquiring a 9.99% beneficial ownership stake in X4 Pharmaceuticals (XFOR) following an August 2025 financing. The Reporting Persons hold an aggregate position equal to 2,479,645 shares of Common Stock on a fully‑diluted basis subject to a beneficial ownership blocker. Coastlands purchased a pre‑funded warrant exercisable for up to 7,047,216 shares for $9,999,999.50 and directly holds 107,500 shares purchased on August 12, 2025 for $1.7074 per share. The August 2025 Financing issued 11,040,776 shares and pre‑funded warrants to investors at $1.42 per share and $1.419 per pre‑funded warrant, respectively, and closed August 13, 2025. The Reporting Persons used working capital to fund their purchase, have registration rights for resale, and note Board changes at the Company including termination of the CEO and CFO and appointments of an Executive Chairman, new CFO and new President.
X4 Pharmaceuticals, Inc. received a Schedule 13D/A disclosing that Growth Equity Opportunities 18 VGE, LLC (GEO) and affiliated NEA entities participated in a private placement that closed on August 13, 2025. GEO purchased 1,734,184 shares of Common Stock at $1.42 per share and pre-funded warrants to acquire 5,311,810 shares at $1.419 each with a $0.001 exercise price, financed from GEO's working capital.
After the transaction GEO directly owns 2,233,744 shares and, taking into account exercisable pre-funded warrants and ownership limitations, has a total deemed ownership of 2,243,658 shares, representing 9.99% of the outstanding common stock based on 22,459,047 shares. The filing states the acquisition was for investment purposes and includes registration rights and related agreements filed by the issuer.
John Volpone, President and Director of X4 Pharmaceuticals, Inc. (XFOR), reported stock awards and option grants on 08/12/2025 and 08/14/2025. The Form 4 discloses 289,881 restricted stock units (RSUs) granted (zero purchase price) that vest one third on each of August 12, 2026, 2027 and 2028, subject to continued service and shareholder approval at the 2026 annual meeting. Two stock option grants were reported: 1,609,873 options at $1.42 (granted 08/12/2025) and 529,201 options at $3.14 (granted 08/14/2025). Each option vests one third on August 12, 2026 with the remainder vesting monthly over 24 months, contingent on continued service. The Form is filed by one reporting person and signed by attorney-in-fact.
Craig Adam R, serving as Executive Chairman and a Director of X4 Pharmaceuticals, Inc. (XFOR), filed an initial Form 3 dated 08/12/2025 reporting that he does not beneficially own any securities of the issuer. The filing includes an Exhibit 24 Power of Attorney and is signed on behalf of the reporting person by an attorney-in-fact on 08/14/2025.
X4 Pharmaceuticals, Inc. (XFOR) filed an initial Form 3 reporting that David Kirske holds the role of Chief Financial Officer and is a reporting person as of the 08/12/2025 event date. The filing states no securities are beneficially owned by the reporting person and lists an Exhibit 24 Power of Attorney. The submission is signed by an attorney-in-fact on 08/14/2025.
Craig Adam R, Executive Chairman and Director of X4 Pharmaceuticals, Inc. (XFOR), reported equity awards in a Form 4 covering transactions on 08/12/2025 and 08/14/2025. The filing shows 289,881 restricted stock units (RSUs) granted (vest one-third each year beginning 08/12/2026, contingent on service and shareholder approval at the 2026 annual meeting). The filing also reports two stock option grants: 1,609,873 options exercisable at $1.42 (vesting beginning 08/12/2026 with remaining vesting monthly over 24 months) and 529,201 options exercisable at $3.14 (granted 08/14/2025). After the reported transactions, the reporting person beneficially owns 289,881 shares and 1,609,873 and 529,201 underlying shares from options, all held directly.
X4 Pharmaceuticals insider filings show equity awards to Chief Financial Officer David Kirske. The Form 4 reports 193,254 restricted stock units granted on 08/14/2025 and two stock option grants recorded on 08/12/2025 and 08/14/2025 covering 1,073,249 and 352,800 underlying shares respectively. The options have exercise prices of $1.42 and $3.14 with expiration dates of 08/12/2035 and 08/14/2035. Vesting schedules are described: RSUs vest one-third on 02/12/2026 then quarterly over 12 months subject to continued service and shareholder approval; options vest 50% on 02/12/2026 then monthly over 12 months with certain performance-based immediate vesting for half if milestones are met before 02/12/2026.
X4 Pharmaceuticals, Inc. (XFOR) Form 3 reports that John Volpone, listed as President and a Director, filed an initial Section 16 statement for the 08/12/2025 event. The filing states no securities are beneficially owned by the reporting person at the time of the statement. The form was signed by an attorney-in-fact on 08/14/2025 and includes an Exhibit 24 power of attorney.
OrbiMed Advisors LLC filed an amended Schedule 13G reporting beneficial ownership of 134,947 warrants of X4 Pharmaceuticals, Inc., representing 1.7% of the company’s common stock on a fully diluted basis. The filing states the warrants confer shared voting and dispositive power over 134,947 warrants and that OrbiMed holds these warrants on behalf of other persons. OrbiMed’s investment and voting authority is exercised through a management committee of three named members, each disclaiming beneficial ownership. The filing affirms the holdings were not acquired to influence control of the issuer.